Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
Volume 0.02M
Average 0.10M
ZYBT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT
Operating Expenses · Q4 FY2025 · quarter ended Dec 2025
Operating expenses of CN¥45.26M in Q4 FY2025
Q4 FY2025 operating expenses was CN¥45.26M. Over 3 fiscal years it compounded at +1.7% a year.
Context
- Operating expenses amounted to 79.2% of revenue in FY2025, up 39.0 pp from a year earlier.
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
CNY · from the income statement
- Latest · FY2025
- 92.12M CNY
- Year-over-year change
- +23.1%
- 4-year CAGR
- +6.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.12M | +23.1% |
| FY2024 | 2024-12-31 | 74.86M | -11.8% |
| FY2023 | 2023-12-31 | 84.87M | -3.2% |
| FY2022 | 2022-12-31 | 87.69M | +20.1% |
| FY2021 | 2021-12-31 | 73.01M | — |
Operating Expenses vs competitors
How ZYBT compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.1% is the 3rd highest of 9, against a peer median of +7.8%.
- Operating expenses amounts to 79.2% of revenue for ZYBT, versus a peer median of 356.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | CN¥92.12M CNY | +23.1% | +1.7% | 79.2% | |
| LTM Mar 2026 | $54.01M USD | -31.7% | -36.0% | — | |
| LTM Mar 2026 | $50.43M USD | +35.5% | -5.6% | 672.9% | |
| LTM Mar 2026 | $36.51M USD | -0.8% | -7.3% | 64043.9% | |
| LTM Mar 2026 | CA$35.59M CAD | +1.4% | +4.2% | — | |
| LTM Mar 2026 | CA$35.46M CAD | +14.2% | +24.6% | — | |
| LTM Mar 2026 | $22.35M USD | -43.7% | -21.5% | 40.0% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $10.15M USD | +53.8% | +101.7% | — |
| LTM Mar 2026 | $9.93M USD | +18.0% | +3.3% | 13.3% | |
| Peer median (excluding ZYBT) | — | +7.8% | -1.2% | 356.4% | |
Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 214.07M | 260.27M | 211.65M | 186.36M | 116.36M |
| Cost of Revenue | 88.67M | 106.75M | 81.8M | 95.06M | 92.49M |
| Gross Profit | 125.39M | 153.52M | 129.86M | 91.3M | 23.87M |
| Gross Margin | 58.6% | 59.0% | 61.4% | 49.0% | 20.5% |
| Research & Development | 11.37M | 13.42M | 11.9M | 12.79M | 18.01M |
| Selling, General & Admin | 58.19M | 63.56M | 66.63M | 63.84M | 74.92M |
| Operating Expenses | 73.01M | 87.69M | 84.87M | 74.86M | 92.12M |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | 25.96M |
| EBITDA | 70.12M | 85.55M | 72.1M | 42.6M | (42.52M) |
| EBITDA Margin | 32.8% | 32.9% | 34.1% | 22.9% | -36.5% |
| Operating Income | 52.38M | 65.83M | 44.99M | 16.44M | (68.25M) |
| Operating Margin | 24.5% | 25.3% | 21.3% | 8.8% | -58.7% |
| Interest Income | 112K | 114K | 312K | 231K | 96K |
| Interest Expense | 1.05M | 2.84M | 4.42M | 4.04M | 3.4M |
| Other Income / Expenses | 683K | (1.92M) | (1.22M) | (2.05M) | (3.62M) |
| Income Before Tax | 53.07M | 63.91M | 43.76M | 14.39M | (71.87M) |
| Pre-Tax Margin | 24.8% | 24.6% | 20.7% | 7.7% | -61.8% |
| Income Tax Expense | 6.6M | 8.17M | 6.25M | 924K | 11.1M |
| Net Income | 38.96M | 46.74M | 31.46M | 11.31M | (69.78M) |
| Net Margin | 18.2% | 18.0% | 14.9% | 6.1% | -60.0% |
| EPS (Basic) | 0.85 | 1.02 | 0.69 | 0.24 | (1.40) |
| EPS (Diluted) | 0.83 | 0.99 | 0.67 | 0.24 | (1.40) |
| Weighted Avg Shares | 45.67M | 45.67M | 45.67M | 47.17M | 47.35M |
| Weighted Avg Shares (Diluted) | 47.17M | 47.17M | 47.17M | 47.17M | 47.35M |
Zhengye Biotechnology Holding Limited
NASDAQ:ZYBT
Intrinsic Alpha fair value
Locked
Current Price
$1.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.